歡迎光臨源葉生物,登錄 | 注冊 |
當前位置: 首頁 > 小分子抑制劑 > Apoptosis > eFT508

瀏覽歷史

S81408

eFT508

源葉(MedMol) 99%
  • 英文名:
  • eFT508
  • 別名:
  • CAS號:
  • 1849590-01-7
  • 分子式:
  • C17H20N6O2
  • 分子量:
  • 340.3797
  • 核磁/質(zhì)譜:
品牌貨號產(chǎn)品規(guī)格價格(RMB) 庫存(上海) 北京 武漢 南京 數(shù)量計量單位 加入購物車...
源葉(MedMol) S81408-1mg 99% ¥400.00元 9 - - - EA 加入購物車
源葉(MedMol) S81408-2mg 99% ¥700.00元 8 - - - EA 加入購物車
源葉(MedMol) S81408-5mg 99% ¥1200.00元 8 - - - EA 加入購物車
源葉(MedMol) S81408-10mg 99% ¥2050.00元 6 - - - EA 加入購物車
源葉(MedMol) S81408-25mg 99% ¥2700.00元 6 - - - EA 加入購物車
源葉(MedMol) S81408-50mg 99% ¥4600.00元 預(yù)計交期:2-3天 - - - EA 加入購物車
源葉(MedMol) S81408-100mg 99% ¥6400.00元 預(yù)計交期:2-3天 - - - EA 加入購物車
大包裝詢價

提交您的電話號碼并同意《個人信息授權(quán)與保護申明》,到貨后將短信提示。
提交

產(chǎn)品介紹

參考文獻

質(zhì)檢證書(COA)

摩爾濃度計算器

相關(guān)產(chǎn)品

  • 提示:詳情請下載說明書。
  • 產(chǎn)品描述: Tomivosertib (eFT508) is a potent, highly selective, and orally active MNK1 and MNK2 inhibitor, with IC50s of 1-2 nM against both isoforms. Tomivosertib (eFT508) treatment leads to a dose-dependent reduction in eIF4E phosphorylation at serine 209 (IC50=2-16 nM) in tumor cell lines. Tomivosertib (eFT508) also dramatically downregulates PD-L1 protein abundance
  • 靶點: MNK1:1-2 nM (IC50);MNK2:1-2 nM (IC50);PD-L1;MNK;?PD-1/PD-L1
  • 體外研究:
    Tomivosertib (eFT508) reduces eIF4E phosphorylation dose-dependently at serine 209 (IC50=2-16 nM) in tumor cell lines. In a panel of appr 50 hematological cancers, Tomivosertib shows anti-proliferative activity against multiple DLBCL cell lines. Sensitivity to Tomivosertib in TMD8, OCI-Ly3 and HBL1 DLBCL cell lines is associated with dose-dependent decreases in production of pro-inflammatory cytokines including TNFα, IL-6, IL-10 and CXCL10. Further evaluation Tomivosertib mechanism of action demonstrates that decreased TNFα production correlates with a 2-fold decrease in TNFα mRNA half-life
  • 體內(nèi)研究:
    Tomivosertib (eFT508) shows significant anti-tumor activity in the TMD8 and HBL-1 ABC-DLBCL models, both of which harbor activating MyD88 mutations. Besides, Tomivosertib combines effectively with components of R-CHOP and with novel targeted agents, including PCI-32765 and Venetoclax, in human lymphoma models
  • 參考文獻:
    1. Kevin R. Webster, et al. eFT508, a Potent and Selective Mitogen-Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 Inhibitor, Is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma (DLBCL). Blood 2015 126:1554. 2. Xu Y, et al. Translation control of the immune checkpoint in cancer and its therapeutic targeting. Nat Med. 2019 Feb;25(2):301-311.
  • 溶解性: soluble  in  DMSO
  • 保存條件: -20℃
  • 配置溶液濃度參考:
    1mg 5mg 10mg
    1 mM 2.938 ml 14.689 ml 29.379 ml
    5 mM 0.588 ml 2.938 ml 5.876 ml
    10 mM 0.294 ml 1.469 ml 2.938 ml
    50 mM 0.059 ml 0.294 ml 0.588 ml
  • 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。
輸入產(chǎn)品批號:

本計算器可幫助您計算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系,公式為:


質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)


  • =
    *
    *


源葉所有產(chǎn)品僅用作科學研究,銷售產(chǎn)品行為均適用于我司網(wǎng)上所列通用銷售條款。